Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eniluracil + 5-FU in Advanced Hepatocellular Carcinoma
NCT00319683Phase 2Terminated
- Sponsor
- Adherex Technologies
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of eniluracil in hepatocellular carcinoma (HCC), sponsored by Adherex Technologies. Primary endpoints: Dose-Limiting Toxicity at Cycle 1 and Maximum Tolerated Dose at Cycle 1. Status: terminated.
02
Drugs
eniluracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00319683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319683.